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ABSTRACT
Background
Increasing efforts and financial resources are being invested in early cancer detection
research. Blood assays detecting tumor biomarkers promise noninvasive and financially
reasonable screening for early cancer with high potential of positive impact on patients’
survival and quality of life. For novel tumor biomarkers, the actual tumor detection limits are
usually unknown and there have been no studies exploring the tumor burden detection limits
of blood tumor biomarkers using mathematical models. Therefore, the purpose of this study
was to develop a mathematical model relating blood biomarker levels to tumor burden.
Methods and Findings
Using a linear one-compartment model, the steady state between tumor biomarker secretion
into and removal out of the intravascular space was calculated. Two conditions were assumed:
(1) the compartment (plasma) is well-mixed and kinetically homogenous; (2) the tumor
biomarker consists of a protein that is secreted by tumor cells into the extracellular fluid
compartment, and a certain percentage of the secreted protein enters the intravascular space
at a continuous rate. The model was applied to two pathophysiologic conditions: tumor
biomarker is secreted (1) exclusively by the tumor cells or (2) by both tumor cells and healthy
normal cells. To test the model, a sensitivity analysis was performed assuming variable
conditions of the model parameters. The model parameters were primed on the basis of
literature data for two established and well-studied tumor biomarkers (CA125 and prostate-
specific antigen [PSA]). Assuming biomarker secretion by tumor cells only and 10% of the
secreted tumor biomarker reaching the plasma, the calculated minimally detectable tumor
sizes ranged between 0.11 mm
3 and 3,610.14 mm
3 for CA125 and between 0.21 mm
3 and
131.51 mm
3 for PSA. When biomarker secretion by healthy cells and tumor cells was assumed,
the calculated tumor sizes leading to positive test results ranged between 116.7 mm
3 and 1.52
310
6 mm
3 for CA125 and between 27 mm
3 and 3.45310
5 mm
3 for PSA. One of the limitations
of the study is the absence of quantitative data available in the literature on the secreted tumor
biomarker amount per cancer cell in intact whole body animal tumor models or in cancer
patients. Additionally, the fraction of secreted tumor biomarkers actually reaching the plasma is
unknown. Therefore, we used data from published cell culture experiments to estimate tumor
cell biomarker secretion rates and assumed a wide range of secretion rates to account for their
potential changes due to field effects of the tumor environment.
Conclusions
This study introduced a linear one-compartment mathematical model that allows estimation
of minimal detectable tumor sizes based on blood tumor biomarker assays. Assuming
physiological data on CA125 and PSA from the literature, the model predicted detection limits
of tumors that were in qualitative agreement with the actual clinical performance of both
biomarkers. The model may be helpful in future estimation of minimal detectable tumor sizes
for novel proteomic biomarker assays if sufficient physiologic data for the biomarker are
available. The model may address the potential and limitations of tumor biomarkers, help
prioritize biomarkers, and guide investments into early cancer detection research efforts.
The Editors’ Summary of this article follows the references.
PLoS Medicine | www.plosmedicine.org August 2008 | Volume 5 | Issue 8 | e170 1287
PLoS MEDICINEIntroduction
Many cancer types are likely curable by conventional
therapies, if detected early enough. Therefore, early detec-
tion is a primary objective of cancer research with a high
potential of improving both patients’ survival and quality of
life. To reach the major goal of these efforts—detection of
cancer in early stages when the disease may still be curable—
currently two types of cancer early detection tests are most
widely studied: blood test(s) and imaging. In both diagnostic
ﬁelds, tremendous progress has been made during the last
decade. Ideally, a less costly highly accurate blood-based
diagnostic biomarker test would precede any further imaging
or biopsy studies. With emerging new, highly sensitive
proteomics test assays there seems to be a nearly limitless
potential to detect traces of tumor biomarkers in patient
serum, if in fact they exist and are speciﬁc enough at early
tumor stages [1–3]. The advances in these test assays pose the
question: What is a realistic lower detectable tumor size limit
for these diagnostic tests? To answer this question for
secreted blood biomarkers, a mathematical compartmental
model simulating the kinetics of blood biomarkers under
varying physiological conditions can be utilized. Many aspects
have to be taken into consideration when a model of a new
test assay is being developed. We chose the setting of ovarian
cancer and prostate cancer to test our model, because they
are among the cancer types that meet the proﬁle for early
detection. Both cancer types often remain relatively asymp-
tomatic until they are advanced and there is likely signiﬁcant
opportunity to improve survival through early detection of
the disease.
Patients diagnosed with early stages of ovarian cancer when
the disease is conﬁned to the ovary have a 5-y survival of up to
95% following conventional therapy. In late stages, however,
the 5-y survival is 25%–30%. Unfortunately, the vast majority
of patients (70%) are still diagnosed in these advanced stages
[4,5]. For ovarian cancer, the tumor biomarker CA125 that is
established for the post-treatment follow up of ovarian
cancer patients has been extensively explored, and data on
mean serum levels in healthy and patient populations, tumor
cell secretion rate, and plasma half-life are available in the
literature [6–8]. Adequate diagnostic tools for the early
detection of ovarian cancer are still missing, but extensive
research in the ﬁeld of novel serum tumor biomarkers and
diagnostic imaging is underway [1,9–13]. Prostate cancer has a
high prevalence in detectable preclinical stages. The intro-
duction of the blood biomarker prostate-speciﬁc antigen
(PSA) for screening of prostate cancer has already caused a
‘‘stage migration’’ [14]. The introduction of screening for
prostate cancer using PSA and digital rectal examination has
resulted in increased detection of prostate cancer in early
stages when the disease is still curable. However, it remains
controversial whether screening for prostate cancer using
this approach has yet had substantial impact on the overall
survival of men with prostate cancer [15]. A high percentage
of men diagnosed with prostate cancer through screening
would not develop symptoms or die of the disease even if left
untreated [16]. On the other hand, aggressive treatment of
those more indolent prostate cancer cases may have harmful
effects and cause signiﬁcant morbidity [17]. Nevertheless,
some authors conclude that men in the general population
without increased risk for prostate cancer in the age range of
50–70 y may beneﬁt from screening with PSA [16].
To our knowledge, there have been no studies exploring
the tumor burden detection limits of serum tumor bio-
markers using mathematical models. Because of increasing
research into early detection of cancer, especially in the
screening use of blood biomarkers, studies using mathemat-
ical models could have an important impact on cancer
detection research [1,18]. Such mathematical models may
address the potential and priority of tumor biomarkers, and
guide investments into research efforts. Moreover, the actual
protein detection limits that are required in order to improve
disease outcome are usually unknown for the emerging blood
biomarkers.
Therefore, the purpose of this study was to develop a
mathematical model to describe the potential detection limits
of tumor burden based on blood biomarkers. To test the
model, a sensitivity analysis was performed using literature
data on two established blood tumor biomarkers for which
relevant model parameter data are available, CA125 and PSA.
Methods
For the compartmental model, the following conditions
were assumed: (1) the compartment represents the plasma,
which is considered well mixed and kinetically homogenous;
(2) the tumor biomarker of interest consists of a protein that
is secreted by tumor cells into the extracellular ﬂuid
compartment, and that a certain percentage of the secreted
protein will enter the intravascular space (plasma) at a
continuous rate. In the plasma, the protein of interest has a
distinct half-life owing to, e.g., degradation by proteases,
hepatic metabolism, or in the case of a smaller protein
because of ﬁltration by the kidney. Two potential pathophy-
siologic conditions were assumed: (1) the tumor biomarker is
either secreted by the tumor cells only (no background
secretion by normal cells) or (2) by tumor cells and to some
extent by healthy normal cells (background secretion by
healthy cells).
The balance (steady state) between protein secretion into
(inﬂow) and protein removal out of the intravascular space
(outﬂow) was calculated using a linear one-compartment
model (Figure 1) [19].
In steady state (no change in biomarker plasma/serum level
with respect to time), the plasma/serum level of the tumor
biomarker can be calculated using formula c as a function of
the inﬂux of tumor biomarker via secretion by normal and
tumor cells into the plasma corrected for the constant
elimination (efﬂux) of the tumor biomarker out of the
plasma/serum (shown in Figure 1). Alternatively, this formula
can also be used to calculate the secretion rate of the tumor
biomarker, if the amount of tumor biomarker in plasma/
serum and the biomarker half-life in plasma/serum is known.
If the tumor biomarker is secreted by tumor cells only
(meaning no secretion by healthy cells is present), the cut-off
level between normal and pathologic tumor biomarker
plasma/serum amounts is basically deﬁned by the detection
limit or sensitivity of the applied protein assay. The more
sensitive the applied protein assay is; the lower will be the
cut-off level for differentiation between healthy and patho-
logic tumor biomarker levels. However, if there is tumor
biomarker secretion by healthy cells in addition to tumor
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pathologic tumor biomarker amounts in serum is substan-
tially higher. Here, a safety margin will likely prevent most
false-positive results. In this case, by subtracting the mean
biomarker level in healthy individuals (steady state reached
by secretion from normal cells) from the biomarker cut-off
level that is deﬁned for differentiation between healthy and
disease (steady state reached by secretion from normal and
tumor cells), the tumor-secreted fraction of the biomarker
level can be derived (steady state reached by secretion from
tumor cells). The tumor-secreted fraction of the biomarker
can then be used to calculate the secretion rate of the
biomarker by tumor cells using formula c (Figure 1). The
calculated secretion rate will represent the tumor biomarker
secretion rate per milliliter serum. However, in order to know
the total extent of tumor biomarker secretion by all tumor
cells, this value has to be extrapolated to the total serum/
plasma volume of the patient. When the extrapolated total
amount of biomarker in the total body plasma/serum volume
is known and the tumor biomarker secretion rate by tumor
cells and the percentage of tumor biomarker reaching the
intravascular space are deﬁned, the required minimal
number of tumor cells secreting the tumor biomarker can
be calculated. Once the minimal tumor cell number is known,
the required minimal tumor size leading to pathologic tumor
biomarker levels in the serum can be estimated [20].
Thus, a model describing the kinetics of serum tumor
biomarker secretion by tumor cells and by normal cells may
be used to relate tumor size to blood biomarker levels. To
further understand limitations of this model, a sensitivity
analysis was performed assuming variable physiologic con-
ditions of the model parameters. For this purpose, the model
parameters were primed on the basis of data in the literature
for two established and well-studied serum tumor bio-
markers, CA125 for ovarian cancer and PSA for prostate
cancer. Through this approach, the potential minimal tumor
size could be calculated that leads to CA125/PSA tumor
biomarker levels in serum detectable by standard clinical or
(in the case of CA125) future hypothetical more sensitive
experimental proteomics blood tests.
General Parameters and Variables of the Tumor Biomarker
Model
The general parameters and variables of the serum tumor
biomarker model are listed in Tables 1 and 2 (CA125) as well
as Tables 3 and 4 (PSA).
CA125
The reported sensitivities for clinically available CA125 II
immunoassays range between detection limits of 0.05 and
1.45 U/ml [6,21]. On the other end of the spectrum are CA125
ELISA assays that are used for research with detection limits
of 5 U/ml [22]. To account for the possibility that newer, more
sensitive proteomics test assays will be developed, a detection
limit as low as 0.01 U/ml was also considered. The cut-off level
for distinction between healthy and disease depends on
whether the biomarker is secreted by normal cells (back-
ground secretion) or by tumor cells only. If the tumor
biomarker is secreted by tumor cells only, the test assay
sensitivity basically deﬁnes the cut-off between healthy and
disease. If there is secretion by healthy cells, the cut-off value
for distinction between healthy and disease has to be set at a
point that offers a high speciﬁcity and beyond which as few of
the normal population as possible will lie. Therefore, in order
to include less than 0.1% of the normal population to the
range of positive test results assuming a Gaussian distribution
of the CA125 levels, the cut-off level was set at 3.09 times the
standard deviations above the mean normal protein serum
level in healthy women (34.11 U/ml). Setting it, e.g., at three
times the standard deviations above the mean value would be
slightly to low. The cut-off level (or more precisely how many
times the standard deviations above the mean normal protein
serum level the cut-off level is set) deﬁnes the percent of test
Figure 1. One-Compartment Model
The kinetics of the serum tumor biomarker in a one-compartment model
can be described with formula a (d/dt reflects the derivative with respect
to time) as a function of tumor biomarker influx via secretion by normal
and tumor cells minus tumor biomarker level at time point t0 times the
elimination rate (efflux) of the biomarker from the intravascular
compartment.
The tumor biomarker concentration in the patient plasma at a given time
point can be described with formula b as a function of tumor biomarker
influx via secretion by normal and tumor cells divided by the elimination
of the biomarker out of the intravascular space corrected for the changes
during the elapsed time.
When time is set to infinity, the steady state of the plasma biomarker
concentration (no change with respect to time) can be calculated as
shown in formula c: the influx of tumor biomarker via secretion by
normal and tumor cells into the plasma corrected for the constant efflux
of the tumor biomarker out of the plasma/serum.
Note: e, Euler’s number (;2.718); Fout, efflux of tumor biomarker via
elimination from the intravascular compartment over time (U/ml/h or
ng/ml/h) (due to degradation/removal); IN, influx of biomarker from
normal healthy cells (U/ml/h or ng/ml/h); IT, inflow of biomarker from
tumor cells (U/ml/h or ng/ml/h); ln, natural logarithm; q0-plasma, tumor
biomarker plasma level at time point t0 (U/ml or ng/ml); qplasma, tumor
biomarker plasma level (U/ml or ng/ml); qsts-plasma, tumor biomarker level
at steady state (U/ml or ng/ml).
doi:10.1371/journal.pmed.0050170.g001
Table 1. General Parameters of the Tumor Biomarker Model
CA125
Parameter Value Reference
Mean plasma/serum volume in a 70-kg
female patient
3,150 ml [31]
Serum half-life of serum tumor biomarker CA125 151.2 h [7]
Mean serum level of tumor biomarker (CA125)
in healthy postmenopausal women
13.1 6 6.8 U/ml [39]
Expected tumor cell density in solid tumor tissue 2 3 10
5/mm
3 [20]
Note: Mean cell density in solid (tumor) tissue¼10
6/mm
3 [20]. To account for the fact that
tumor tissue contains other cells besides tumor cells and that ovarian tumors tend to
have cystic components: only 20% of mean total number of cells in tissue volume were
considered to be actual tumor cells ¼ 2 3 10
5/mm
3.
doi:10.1371/journal.pmed.0050170.t001
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positive test results. However, to account for different test
situations, a sensitivity analysis with regard to varying
probabilities of false positive test results was performed.
Therefore, a total range of 0.01–34.11 U/ml was used as cut-
off level.
Not all of the protein secreted by the cells into the
extracellular ﬂuid compartment will reach the intravascular
space. A range of 0.1%–20% mean percentages of secreted
tumor biomarker getting into the intravascular space was
assumed.
The secretion rate of CA125 into cell culture medium by
selected ovarian cancer cell lines (OVCAR-3, SK-OV-8, SK-
OV-3 secreting 2–13 U/10
5 cells/20 h/ml medium) has been
reported by Zeimet et al [6]. As the results of the study by
Zeimet et al. represent cell culture data, a wider range of
secretion rates (up to 130 U/10
5 cells/20 h/ml medium) was
used for the model to account for potential enhancing
inﬂuences of the tumor microenvironment (ﬁeld effects) on
the actual tumor biomarker secretion.
PSA
The reported sensitivities for clinically available PSA
immunoassays range between detection limits of 0.01 ng/ml
and 0.1 ng/ml [14,23,24]. As mentioned before, the cut-off
level for the distinction between healthy and disease depends
on whether the blood biomarker is secreted by normal cells
or by tumor cells only. If there were no background secretion
of PSA by normal cells, the highly sensitive immunoassays
that are clinically available for PSA would allow for very low
cut-off levels. However, there is background secretion of PSA
by nonmalignant prostate cells. PSA serum values are known
to increase with increasing prostate volumes as in benign
prostate hyperplasia, a condition that is highly prevalent in
older men [25]. In screening for prostate cancer, the
American Urological Association recommends to proceed
to prostate biopsy in patients exceeding the PSA cut-off level
4 ng/ml [26]. Some authors even recommend prostate biopsies
at PSA levels of 2.6–4 ng/ml in men younger than 60 y [27]. Up
to 25% of the more aggressive prostate cancer types are
found in men with PSA levels below 4 ng/ml, but despite this
fact there is fear that lowering the cut-off level might result in
overdiagnosing and overtreatment of prostate cancer [17].
For our model, therefore, we chose the widely recommended
cut-off level of 4 ng/ml to differentiate between healthy and
disease state. This value is actually close to a cut-off level
calculated by adding 3.09 3 the standard deviation to the
mean PSA level in healthy 50- to 59-y-old men (4.161 ng/ml)
[28] . Since normal values of PSA are age dependent, we used
a published normal value of 1.38 ng/ml for the age group of
50- to 59-y-old men [28].
A range of 0.1%–20% of secreted tumor biomarker getting
into the intravascular space was assumed.
Reported PSA secretion rates by the prostate cancer cell
line LNCaP are 21 ng/10
5 cells/ml/24 h and 134 ng/10
6 cells/ml/
24 h, respectively [29,30]. In order to account for tumor cell
types that might secrete lower amounts of PSA and for
potential inﬂuences on the cell secretion by the tumor
microenvironment (ﬁeld effects), we chose a broader range of
secretion rates for our calculations and added secretion rates
as low as 2.1 ng/10
5 cells/ml/24 h and 10-fold higher than the
published value of 134 ng/10
6 cells/ml/24 h (up to a maximum
of 1,340 ng/10
6 cells/ml/24 h) to the analysis.
Results
Using a linear one-compartment model, the tumor
biomarker level in patient plasma under steady state
conditions was described as a function of either tumor
biomarker secretion by tumor cells or, if applicable, by
healthy normal cells (inﬂux) and tumor biomarker plasma
half-life (efﬂux) (Figure 1).
CA125 Secretion by Tumor Cells Only
When no biomarker secretion by healthy cells was assumed,
the required tumor size resulting in detectable CA125 levels
was deﬁned by the actual detection limit or sensitivity of the
proteomics assay (model variables, Table 2). In that case,
under the assumption of a percentage of 10% of the secreted
tumor biomarker reaching the intravascular space, the
Table 3. General Parameters of the Tumor Biomarker Model PSA
Parameter Value Reference
Mean plasma/serum volume in a 85-kg-male
patient
3,825 ml [31]
Serum half-life of serum tumor biomarker PSA 46.08 h [45]
Mean serum level of tumor biomarker (PSA) in
healthy men, age 50–59 y
1.38 6 0.9 ng/ml [28]
Expected tumor cell density in solid tumor tissue 5 3 10
5/mm
3 [20]
Note: Mean cell density in solid (tumor) tissue¼10
6/mm
3 [20]. To account for the fact that
tumor tissue contains other cells besides tumor cells: only 50% of mean total number of
cells in tissue volume were considered to be actual tumor cells ¼ 5 3 10
5/mm
3.
doi:10.1371/journal.pmed.0050170.t003
Table 2. Variables Used to Test the Tumor Biomarker Assay Model CA125
Variable Baseline Range References
Sensitivity of blood proteomics test 1.45 U/ml 0.01–5 U/ml [6,21,22]
Cut-off level for distinction between healthy and disease — 0.01–34.11 U/ml [6,8,21,22]
Percentage of false positive test assay results 0.1 % 0.1%–5% —
Fraction of secreted protein reaching plasma 10 % 0.1%–20% —
Tumor biomarker secretion rate by tumor cells — 2–130 U/10
5 cells/20 h/ml [6]
Note: In order to account for potential field effects of the tumor microenvironment on the biomarker secretion rates we chose a broader range of CA125 secretion rates up to 10-fold
higher than those published in the literature.
doi:10.1371/journal.pmed.0050170.t002
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levels in patients’ plasma/serum ranged between 0.11 mm
3
and 3,610.14 mm
3 depending on the assumed tumor cell
secretion rates and sensitivity of the blood assay (Table 5).
Under the assumption of an assay sensitivity of 1.45 U/ml
(clinically realistic conditions) and 10% of tumor biomarker
reaching the plasma/serum, the detectable tumor sizes ranged
between 16.11 mm
3 and 1,046.94 mm
3.
CA125 Secretion by Tumor Cells and Healthy Cells
When biomarker secretion by healthy cells is present (a
more likely scenario), it was assumed that the secretion of
CA125 by healthy cells accounts for up to 13.1 U/ml, and that
tumor cells contribute the rest of the secretion up to the
required cut-off level. The calculated tumor biomarker
secretion by healthy cells was 0.06 U/ml/h, and the secretion
rate by tumor cells was 0.10 U/ml/h. Extrapolated to the total
body plasma volume (3,150 ml) the tumor biomarker
secretion rate by healthy cells and by tumor cells was 189.17
U/3,150 ml/h and 303.43 U/3,150 ml/h, respectively, assuming a
test assay cut-off level of 34.11 U/ml. Taking into account the
varying tumor biomarker secretion rates, the calculated
tumor sizes leading to positive test results (over the cut-off
level of 34.11 U/ml patient serum) ranged between 116.7 mm
3
and 1.52 3 10
6 mm
3 (1.52 l) under the assumption of 10% of
the secreted tumor biomarker reaching the plasma (Table 6).
CA125—Influence of Protein Assay Cut-off Level/Test
Specificity on Tumor Size
Assuming a Gaussian distribution of protein tumor
biomarker levels in healthy controls, 10% of the secreted
tumor biomarker reaching the plasma, and that the minimum
detection limit of the assay is 1.45 U/ml, the minimally
detectable tumor sizes ranged between 123.88 and 15,171.26
mm
3 depending on the chosen probability of false positive
test results (Table 7).
PSA Secretion by Tumor Cells Only
When no biomarker secretion by healthy cells was assumed,
the required tumor size resulting in detectable PSA levels was
deﬁned by the actual detection limit or sensitivity of the
proteomics assay (model variables, Table 4). Under the
assumption of 10% of the secreted tumor biomarker reach-
ing the intravascular space, the calculated tumor sizes leading
to detectable PSA levels in patients’ serum ranged between
0.21 mm
3 and 131.51 mm
3 depending on the assumed tumor
cell secretion rates and sensitivity of the blood assay (Table 8).
When an assay sensitivity of 0.04 ng/ml (clinically realistic
conditions) and 10% of tumor biomarker reaching the
plasma/serum were assumed, the detectable tumor sizes
ranged between 0.82 mm
3 and 52.6 mm
3. Even an assay
sensitivity of 0.01 ng/ml would still be clinically realistic and
then decrease the detection levels to a range of 0.21 to 13.15
mm
3 under the assumption of 10% of the secreted PSA
reaching the intravascular space.
PSA Secretion by Tumor Cells and Healthy Cells
PSA is also secreted to some extent by nonmalignant cells.
When biomarker secretion by healthy cells is present, it was
assumed that the secretion of PSA by healthy cells accounts
for 1.38 ng/ml (normal value for 50- to 59-y-old men) and
secretion by tumor cells accounts for the remaining 2.62 ng/
ml up to the cut-off level of 4 ng/ml. The calculated
Table 4. Variables Used to Test the Tumor Biomarker Assay Model PSA
Variable Baseline Range References
Sensitivity of blood proteomics test 0.04 ng/ml 0.01–0.1 ng/ml [14,23,24]
Cut-off level for distinction between healthy and disease 4 ng/ml — [26]
Fraction of secreted PSA reaching plasma 10% 0.1%–20% —
Tumor biomarker secretion rate by tumor cells — 2.1–134 ng/10
5 cells/24 h/ml [29,30]
Note: In order to account for potential field effects of the tumor microenvironment on the biomarker secretion rates we chose a broader range of PSA secretion rates (up to 10-fold lower
and higher than published in the literature).
doi:10.1371/journal.pmed.0050170.t004
Table 5. Minimum Detectable Tumor Cell Number and Estimated Tumor Size (in mm
3) as a Function of CA125 Proteomics Test Assay
Sensitivity
Biomarker Secretion Rate Detection Limit of Proteomics Test Assay
0.01 U/ml 0.05 U/ml 0.1 U/ml 1.45 U/ml 5 U/ml
Increased tumor cell secretion in tumor microenvironment
(6.5 U/ml/h/10
5 cells); 10% of tumor marker getting into plasma
2.22 3 10
4
(0.11 mm
3)
1.11 3 10
5
(0.56 mm
3)
2.22 3 10
5
(1.11 mm
3)
3.22 3 10
6
(16.11 mm
3)
1.11 3 10
7
(55.54 mm
3)
Tumor cells secreting high amounts of tumor marker
(0.65 U/ml/h/10
5 cells); 10% of tumor marker getting into plasma
2.22 3 10
5
(1.11 mm
3)
1.11 3 10
6
(5.55 mm
3)
2.22 3 10
6
(11.11 mm
3)
3.22 3 10
7
(161.07 mm
3)
1.11 3 10
8
(555.41 mm
3)
Tumor cells secreting intermediate amounts of tumor marker
(0.45 U/ml/h/10
5 cells); 10% of tumor marker getting into plasma
3.21 3 10
5
(1.60 mm
3)
1.6 3 10
6
(8.02 mm
3)
3.21 3 10
6
(16.05 mm
3)
4.65 3 10
7
(232.65 mm
3)
1.6 3 10
8
(802.25 mm
3)
Tumor cells secreting low amounts of tumor marker
(0.1 U/ml/h/10
5 cells); 10% of tumor marker getting into plasma
1.44 3 10
6
(7.2 mm3)
7.22 3 10
6
(36.10 mm
3)
1.44 3 10
7
(72.20 mm
3)
2.09 3 10
8
(1,046.94 mm
3)
7.22 3 10
8
(3,610.14 mm
3)
doi:10.1371/journal.pmed.0050170.t005
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Extrapolated to the total body plasma volume (3,825 ml) the
biomarker secretion rate by tumor cells was 150.75 ng/3,825
ml/h assuming a test assay cut-off level of 4 ng/ml. Taking into
account the varying tumor biomarker secretion rates, the
calculated tumor sizes leading to positive test results (over the
cut-off level of 4 ng/ml patient serum) ranged between 27
mm
3 and 3.45 3 10
5 mm
3 (0.35 l) under the assumption of
10% of the secreted tumor biomarker reaching the plasma
(Table 9).
Discussion
The aim of this study was to relate serum tumor biomarker
levels as detected by a blood assay to detectable tumor sizes,
because such a relationship can likely aid in determining the
lower limit for detectable tumor sizes. A linear one-compart-
ment model (Figure 1) was used to describe the pharmaco-
kinetics of a protein serum tumor biomarker in blood,
including tumor biomarker secretion by tumor cells (and
healthy cells, if background biomarker secretion is also
present), transfer to the intravascular space, and ﬁnal
degradation and/or removal from the plasma (represented
as outﬂow [Fout] in the model). By priming the model
parameters on the basis of the literature data for two
established and well-studied tumor biomarkers, CA125 for
ovarian cancer and PSA for prostate cancer, the potential
detection limits needed for a proteomic blood test with
regards to tumor burden were calculated under varying
physiological and assay conditions (Tables 1–4) [6–8,14,20–
24,26,28–31]. A sensitivity analysis of the model (by varying
model parameters over a range of parameter assumptions)
resulted in a wide range of minimally detectable tumor sizes
depending on the speciﬁc chosen conditions. In the ideal case
scenario of a novel serum tumor biomarker that is secreted
only by tumor cells, depending on the chosen parameters
(tumor biomarker secretion rate, its fraction reaching the
plasma, and the available blood test assay sensitivity), very
small ovarian cancer lesions down to a size of 0.11–7.22 mm
3
may be detected with a highly sensitive blood assay. Assuming
the same ideal case scenario of exclusive biomarker secretion
by tumor cells for prostate cancer, comparably small lesions
in a range of 0.21–13.15 mm
3 may be detectable even with a
clinically available PSA immunoassay (detection limit 0.01 ng/
ml). In a clinically more realistic scenario, however, with
additional secretion of the serum tumor biomarker by
healthy cells, ovarian cancer lesions between 116.7 mm
3 and
1.52310
6 mm
3 (1.52 l), roughly corresponding to a size range
between 4.89
3 mm
3 and 114.98
3 mm
3, may be detected
depending on the chosen physiological and model parame-
ters.
In our study, the minimal tumor lesion sizes obtained by
the sensitivity analysis under the assumption of tumor
biomarker secretion by healthy cells (it is known that healthy
mesothelial cells secrete CA125 [6]) ranged between several
hundred mm
3 and more than 10
6 mm
3 for ovarian cancer.
Indeed, these results are in qualitative agreement with the
performance of CA125 in clinical applications. CA125 tests
are positive in up to 80% of patients with advanced stage
disease (e.g., tumor volumes up to 10
6 mm
3 are reported for
advanced ovarian cancer with peritoneal metastases [32]), but
are negative in up to 50% of patients with stage I disease
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Mathematical Modeling of Blood Biomarker Levelswhen the tumor burden is still limited [33–35]. Likewise, in a
clinically more realistic scenario for PSA with background
secretion of PSA also by healthy prostatic cells, we found that
tumor lesions ranged in size between 27 mm
3 and 3.45 3 10
5
mm
3 (0.35 l), which approximately corresponds to a size range
between 3
3 mm
3 and 70.14
3 mm
3 that can be detected by a
serum marker test. Again, these size ranges largely depend on
the physiological and model parameters chosen for the
model. In the clinic, PSA serum levels are known to positively
correlate with prostate cancer size. However, even at low PSA
levels of 4 ng/ml, a tumor as big as 10,000 mm
3 can already be
present, underlining the large physiological variability of
tumor marker secretion by tumors in patients [36].
When biomarker secretion by tumor and normal cells were
assumed and sensitivities of clinically available proteomics
assays were used for our model analysis, the calculated
minimally detectable tumor sizes were smaller for PSA than
for CA125 in our study, but still in a comparable range. This
may seem surprising, given the much lower cut-off level for
differentiation between healthy and disease state for PSA (4
ng/ml) compared with CA125 (34.11 U/ml), the chosen higher
tumor cell density for prostate tumors than for ovarian
tumors and the comparable range of both biomarker
secretion rates. The different measurement units (units/ml
for CA125 versus ng/ml for PSA) do not actually matter in this
mathematical model, since they cancel each other out during
the calculations. However, the plasma half-life is much
shorter for PSA than for CA125 (46.08 h for PSA versus
151.2 h for CA125), and the chosen average plasma volume is
much larger for men than for women (3,825 ml for men
versus 3,150 ml for women) [31]. Therefore, because of the
shorter PSA plasma half-life as well as the larger plasma
volume in men, more PSA has to be secreted by prostate
tumors to reach a steady state level detectable with
proteomics assays. These facts may explain why the calculated
minimally detectable tumor sizes were within a comparable
range for both biomarkers despite the fact that PSA has a
lower cut-off level than CA125.
We acknowledge that CA125 and PSA are not ideal cancer
screening biomarkers. CA125 is considered a valuable
biomarker for assessing therapeutic success in ovarian cancer
patients rather than being used as a diagnostic screening
biomarker [37]. PSA is often considered too sensitive and not
speciﬁc enough for screening purposes of prostate cancer
since the number of false positive results is too high for PSA.
Increased PSA levels are also found at high percentages in
patients with benign prostatic hypertrophy, a disorder with
high prevalence in the older male population [38]. Accord-
Table 7. Minimum Detectable Tumor Cell Number and Estimated Tumor Size (in mm
3) as a Function of CA125 Proteomics Test Assay
Cut-Off Level/Specificity of Test Results
Biomarker Secretion Rate Percentage of False Positive Test Results (Cut-Off Level)
5% (24.25) 2% (27.04) 1% (28.94) 0.1% (34.11)
Increased tumor cell secretion in tumor microenvironment
(6.5 U/ml/h/10
5 cells); 10% of tumor marker getting into plasma;
minimum detection limit of proteomics test 1.45 U/ml
2.48 3 10
7
(123.88 mm
3)
3.1 3 10
7
(154.85 mm
3)
3.52 3 10
7
(176.0 mm
3)
4.67 3 10
7
(233.4 mm
3)
Tumor cells secreting high amounts of tumor marker
(0.65 U/ml/h/10
5 cells); 10% of tumor marker getting into plasma;
minimum detection limit of proteomics test 1.45 U/ml
2.48 3 10
8
(1,238.78 mm
3)
3.1 3 10
8
(1,548.47 mm
3)
3.52 3 10
8
(1,759.97 mm3)
4.68 3 10
8
(2,334.04 mm
3)
Tumor cells secreting intermediate amounts of tumor marker
(0.45 U/ml/h/10
5 cells); 10% of tumor marker getting into plasma;
minimum detection limit of proteomics test 1.45 U/ml
3.58 3 10
8
(1,789.35 mm
3)
4.47 3 10
8
(2,236.68 mm
3)
5.08 3 10
8
(2,542.18 mm
3)
6.74 3 10
8
(3,371.39 mm
3)
Tumor cells secreting low amounts of tumor marker
(0.1 U/ml/h/10
5 cells); 10 % of tumor marker getting into plasma;
minimum detection limit of proteomics test 1.45 U/ml
1.61 3 10
9
(8,052.06 mm
3)
2.01 3 10
9
(10,065.07 mm
3)
2.29 3 10
9
(11,439.82 mm
3)
3.03 3 10
9
(15,171.26 mm
3)
doi:10.1371/journal.pmed.0050170.t007
Table 8. Minimum Detectable Tumor Cell Number and Estimated Tumor Size (in mm
3) as a Function of PSA Proteomics Test Assay
Sensitivity
Biomarker Secretion Rate Detection Limit of Proteomics Test Assay
0.01 ng/ml 0.04 ng/ml 0.08 U/ml 0.1 ng/ml
Increased tumor cell secretion in tumor microenvironment
(5.58 ng/ml/h/10
5 cells); 10% of tumor marker getting into plasma
1.03 3 10
5
(0.21 mm
3)
4.12 3 10
5
(0.82mm
3)
8.24 3 10
5
(1.65 mm
3)
1.03 3 10
6
(2.06 mm
3)
Tumor cells secreting high amounts of tumor marker
(0.88 ng/ml/h/10
5 cells); 10% of tumor marker getting into plasma
6.58 3 10
5
(1.32 mm
3)
2.63 3 10
6
(5.26mm
3)
5.26 3 10
6
(10.52 mm
3)
6.58 3 10
6
(13.15 mm
3)
Tumor cells secreting intermediate amounts of tumor marker
(0.56 ng/ml/h/10
5 cells); 10% of tumor marker getting into plasma
1.03 3 10
6
(2.06 mm
3)
4.12 3 10
6
(8.24 mm
3)
8.24 3 10
6
(16.49 mm
3)
1.03 3 10
7
(20.61 mm
3)
Tumor cells secreting low amounts of tumor marker
(0.09 ng/ml/h/10
5 cells); 10% of tumor marker getting into plasma
6.58 3 10
6
(13.15 mm
3)
2.63 3 10
7
(52.6 mm
3)
5.26 3 10
7
(105.21 mm
3)
6.58 3 10
7
(131.51 mm
3)
doi:10.1371/journal.pmed.0050170.t008
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Mathematical Modeling of Blood Biomarker Levelsingly, ‘‘normal’’ PSA levels are closely linked to age and
prostate gland size, which is reﬂected by increasing PSA
serum levels with increasing age [28]. On the other hand, high
grade cancers, which have an aggressive clinical course with
early metastasis and, thus, need to be detected at very early
stage for a curative treatment, can present with PSA levels
smaller than 4 ng/ml in up to 25% of cases [17]. However, we
chose these two serum tumor biomarkers for our study
because both markers are among the most widely studied
tumor biomarkers and many physiological parameters such as
in vitro secretion rates in tumor cell culture studies, blood
half-life in healthy men and women, and normal serum levels
in cohorts of healthy individuals have been published in the
literature and can be applied in the our model. The choice of
these biomarkers is not because we in any way advocate their
use in early cancer detection, but as stated above, because not
enough data exist on almost all biomarkers relevant for the
type of modeling performed in our study.
For PSA we performed the sensitivity analysis assuming the
clinically established and widely recommended cut-off level
of 4 ng/ml for differentiating between presence of tumor and
no tumor [26]. In general, for a novel biomarker the cut-off
level of a novel biomarker test assay has to be optimized to
reduce the number of false positive results causing unneces-
sary follow-up examinations or therapies following a positive
screening test. Therefore, a wide safety margin above the
mean level in healthy controls is usually chosen to increase
the assay speciﬁcity. For CA125 in our study, we set the cut-
off level at 3.09 times the standard deviation (at 34.11 U/ml)
above the mean CA125 value found in healthy postmeno-
pausal women (13.1 U/ml), thereby excluding 99.9% of
healthy individuals from false positive test results in our
model. The cut-off value of 34.11 U/ml in our study is actually
very close to the cut-off limit of 35 U/ml that was originally
reported for CA125 tests to differentiate benign from
malignant disease in patients [39]. With our mathematical
model we are also able to show the inﬂuence of test speciﬁcity
on potential detection limits of a tumor blood biomarker
assay. However, this demonstration does not take into
account that very high test speciﬁcity may result in low test
sensitivity and thus result in a high likelihood of false-
negative test results. In order to calculate sensitivity,
accuracy, and positive/negative predictive values of a blood
biomarker assay, however, the mean level and standard
deviation of the diseased population’s blood tumor bio-
marker would need to be further speciﬁed.
Extensive research in the ﬁeld of biomarkers for early
detection of ovarian cancer is currently underway with many
promising candidates emerging over the last few years [1].
Our model clearly points out that blood biomarkers that are
speciﬁc for a malignant disease are more desirable than
nonspeciﬁc biomarkers that are also secreted by nonmalig-
nant cells. For example, in the ideal scenario of a highly
speciﬁc biomarker that is not secreted by healthy cells there is
the potential to detect early-stage tumors as small as 0.11–
13.15 mm
3 on the basis of our calculations. In addition, a
combination of two or more highly speciﬁc tumor bio-
markers may further increase performance of biomarker
screening for ovarian cancer, especially if they complement
each other. It is expected that the currently available
biomarker CA125 may be used as part of a panel of serum
tumor biomarkers [40,41]. Actually our model may even be
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Mathematical Modeling of Blood Biomarker Levelsextended to accommodate the concept of a biomarker panel
by combining multiple one-compartment models each with
distinct parameters for a given distinct biomarker protein.
Furthermore, our model is not limited to biomarkers for
ovarian or prostate cancer and can be applied to any type of
tumor secreting distinctive biomarkers that ﬁnd access to the
bloodstream and that can be measured in patient serum
samples.
The following limitations of our model need to be
addressed. To the best of our knowledge, there are no
quantitative values available in the literature on the amount
of secreted tumor biomarker per cancer cell in intact whole
body animal tumor models or in patients with any type of
cancer. In addition, the fraction of secreted tumor biomarkers
actually reaching the intravascular space in animal tumor
models or in patients with cancer has not been determined in
the literature to date. Therefore, we used data from published
cell culture experiments to estimate tumor cell secretion rates
of the biomarker, and we assumed a wide range of secretion
rates to account for potential changes in tumor biomarker
secretion rates due to the effects of the tumor environment in
intact living individuals. Furthermore, the tumor biomarker
secretion rate from tumor and/or normal healthy cells may
change over time in a patient with cancer causing the tumor
biomarker plasma concentration to vary at different time
points (e.g., circadian variation). A modiﬁcation of the linear
one-compartment ﬂow model (comparable to the principle of
repeated extravascular dosing [42]) may account for time-
dependent changes of tumor biomarker secretion and is
currently under investigation. As soon as more detailed data
on these varying physiologic processes in patients with
ovarian, prostate, or other cancer become available in the
literature, our model could be modiﬁed to account for such
time-dependent changes in protein secretion rates. Further-
more, the model is suitable for the wide variety of secreted
protein blood markers, but not for other important novel
classes of blood tumor biomarkers such as auto-antibodies
that are targeted against tumor antigens and can be found in
patient blood samples. Currently, the model also does not
account for changes in the tumor microenvironment that
might occur very early in a developing cancer when there
might be nonsecreted biomarkers present (e.g., biomarkers
that get cleaved from tumor cells by interaction with
proteases) [43,44].
In conclusion, in this study we introduced a linear one-
compartment mathematical model that allows estimation of
minimal detectable tumor sizes on the basis of blood tumor
biomarker assays. Assuming physiological data on CA125 and
PSA from the literature, the reported mathematical model
predicted detection limits of ovarian and prostate tumors that
are in qualitative agreement with the actual clinical perfor-
mance of the biomarkers. Our mathematical model may be
helpful in future estimation of minimal detectable tumor sizes
for novel proteomic biomarker assays if sufﬁcient physiologic
data for the biomarker are available. Important basic studies
that scientists in the cancer diagnostics ﬁeld should consider
when exploring the potential of novel biomarkers include
biomarker testing of secretion rates in cell culture studies and
testing of biomarker half-life in patients undergoing treat-
ment. Future experiments in (animal) models of biomarker
secretion such as reporter models may reveal the required
data for in vivo biomarker cell secretion rates, inﬂuence of
tumor microenvironment on biomarker secretion rates, and
the percentage of tumor marker reaching the intravascular
space. A reporter model, e.g., with xenografts/allografts of
tumor cell lines that are modiﬁed to secrete a unique
experimental ‘‘biomarker’’ may be helpful to relate tumor
sizes to biomarker blood levels more reliably. Furthermore,
models in which secretion of a biomarker is coupled to
simultaneous expression/secretion of a ﬂuorescent dye may
help characterize the extents of secreted biomarkers reaching
the intravascular space. It is not easy to develop and
implement these models, but they are potentially very
important since they may help us understand the physiolog-
ical processes of in vivo biomarker cell secretion.
Acknowledgments
We would like to thank Jarret Rosenberg, Ph.D., Department of
Radiology, Stanford University, for his help with statistical issues.
Author contributions. SSG designed the mathematical model/
strategy. AML, JKW, and SSG designed the experiments/the study.
AML and JKW collected data or did experiments for the study. AML
and SSG analyzed the data. AML and SSG wrote the first draft of the
paper. AML, JKW, FVC, PR, and SSG contributed to the writing of the
paper.
References
1. Williams TI, Toups KL, Saggese DA, Kalli KR, Cliby WA, et al. (2007)
Epithelial ovarian cancer: disease etiology, treatment, detection, and
investigational gene, metabolite, and protein biomarkers. J Proteome Res
6: 2936–2962.
2. Engwegen JY, Gast MC, Schellens JH, Beijnen JH (2006) Clinical proteomics:
searching for better tumour markers with SELDI-TOF mass spectrometry.
Trends Pharmacol Sci 27: 251–259.
3. Lopez MF, Mikulskis A, Kuzdzal S, Golenko E, Petricoin EF 3rd, et al. (2007)
A novel, high-throughput workﬂow for discovery and identiﬁcation of
serum carrier protein-bound peptide biomarker candidates in ovarian
cancer samples. Clin Chem 53: 1067–1074.
4. Del Carmen MG (2006) Primary epithelial ovarian cancer: diagnosis and
management. Educational Book Manuscript of the American Society of
Clinical Oncology: 330–334. Available: http://www.asco.org/ASCO/
Educationþ%26þTraining/Education/EducationalþBook?&vmview¼edbk_
detail_view&confID¼40&abstractID¼330. Accessed 11 July 2008.
5. Chan JK, Cheung MK, Husain A, Teng NN, West D, et al. (2006) Patterns
and progress in ovarian cancer over 14 years. Obstet Gynecol 108: 521–528.
6. Zeimet AG, Marth C, Offner FA, Obrist P, Uhl-Steidl M, et al. (1996) Human
peritoneal mesothelial cells are more potent than ovarian cancer cells in
producing tumor marker CA-125. Gynecol Oncol 62: 384–389.
7. Mastropaolo W, Fernandez Z, Miller EL (1986) Pronounced increases in the
concentration of an ovarian tumor marker, CA-125, in serum of a healthy
subject during menstruation. Clin Chem 32: 2110–2111.
8. Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, et al. (2001)
Factors inﬂuencing serum CA125II levels in healthy postmenopausal
women. Cancer Epidemiol Biomarkers Prev 10: 489–493.
9. McIntosh MW, Urban N (2003) A parametric empirical Bayes method for
cancer screening using longitudinal observations of a biomarker. Biosta-
tistics 4: 27–40.
10. Risum S, Hogdall C, Loft A, Berthelsen AK, Hogdall E, et al. (2007) The
diagnostic value of PET/CT for primary ovarian cancer–a prospective
study. Gynecol Oncol 105: 145–149.
11. van Nagell JR Jr., DePriest PD, Ueland FR, DeSimone CP, Cooper AL, et al.
(2007) Ovarian cancer screening with annual transvaginal sonography:
ﬁndings of 25,000 women screened. Cancer 109: 1887–1896.
12. Testa AC, Timmerman D, Exacoustos C, Fruscella E, Van Holsbeke C, et al.
(2007) The role of CnTI-SonoVue in the diagnosis of ovarian masses with
papillary projections: a preliminary study. Ultrasound Obstet Gynecol 29:
512–516.
13. Okada T, Harada M, Matsuzaki K, Nishitani H, Aono T (2001) Evaluation of
female intrapelvic tumors by clinical proton MR spectroscopy. J Magn
Reson Imaging 13: 912–917.
14. Gregorakis AK, Stefanakis S, Malovrouvas D, Petraki K, Gourgiotis D, et al.
(2008) Total and free PSA kinetics in patients without prostate cancer
undergoing radical cystoprostatectomy. Prostate 68: 759–765.
15. Raghavan D (2008) Prostate cancer: too much dogma, not enough data.
Cleve Clin J Med 75: 33–34.
16. Lamb DS, Slaney D, Smart R, Nacey JN, Russell G, et al. (2007) Prostate
cancer: the new evidence base for diagnosis and treatment. Pathology 39:
537–544.
17. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, et al. (2004)
PLoS Medicine | www.plosmedicine.org August 2008 | Volume 5 | Issue 8 | e170 1295
Mathematical Modeling of Blood Biomarker LevelsPrevalence of prostate cancer among men with a prostate-speciﬁc antigen
level , or ¼ 4.0 ng per milliliter. N Engl J Med 350: 2239–2246.
18. Jacobs I (2005) Screening for familial ovarian cancer: the need for well-
designed prospective studies. J Clin Oncol 23: 5443–5445.
19. Lassen NA, Perl W (1979) Tracer kinetic methods in medical physiology.
New York: Raven Press.
20. Enderle J, Blanchard S, Bronzino J (2005) Introduction to biomedical
engineering. Amsterdam and Boston: Elsevier Academic Press. 375 p.
21. Mongia SK, Rawlins ML, Owen WE, Roberts WL (2006) Performance
characteristics of seven automated CA 125 assays. Am J Clin Pathol 125:
921–927.
22. Alpco (2007) AD (User manual) Cancer Antigen CA125 ELISA. Available:
www.alpco.com. Accessed 11 July 2008.
23. Haese A, Huland E, Graefen M, Hammerer P, Noldus J, et al. (1999)
Ultrasensitive detection of prostate speciﬁc antigen in the followup of 422
patients after radical prostatectomy. J Urol 161: 1206–1211.
24. Jung K, Stephan C, Lein M, Henke W, Schnorr D, et al. (1996) Analytical
performance and clinical validity of two free prostate-speciﬁc antigen
assays compared. Clin Chem 42: 1026–1033.
25. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, et al. (2004) The
prostate speciﬁc antigen era in the United States is over for prostate
cancer: what happened in the last 20 years? J Urol 172: 1297–1301.
26. American Urological Association (AUA) (2000) Prostate-speciﬁc antigen
(PSA) best practice policy. Oncology 14: 267–272, 277–268, 280 passim.
27. Punglia RS, D’Amico AV, Catalona WJ, Roehl KA, Kuntz KM (2003) Effect
of veriﬁcation bias on screening for prostate cancer by measurement of
prostate-speciﬁc antigen. N Engl J Med 349: 335–342.
28. Chun FK, Perrotte P, Briganti A, Benayoun S, Lebeau T, et al. (2006)
Prostate speciﬁc-antigen distribution in asymptomatic Canadian men with
no clinical evidence of prostate cancer. BJU Int 98: 50–53.
29. Graeser R, Chung DE, Esser N, Moor S, Schachtele C, et al. (2008) Synthesis
and biological evaluation of an albumin-binding prodrug of doxorubicin
that is cleaved by prostate-speciﬁc antigen (PSA) in a PSA-positive
orthotopic prostate carcinoma model (LNCaP). Int J Cancer 122: 1145–
1154.
30. McCann MJ, Gill CI, Linton T, Berrar D, McGlynn H, et al. (2008)
Enterolactone restricts the proliferation of the LNCaP human prostate
cancer cell line in vitro. Mol Nutr Food Res 52: 567–580.
31. Warrel DA, Cox TM, Firth JD, Benz EJ (2003) Oxford textbook of medicine.
Oxford and New York: Oxford University Press.
32. Mahlck CG, Grankvist K, Kjellgren O, Backstrom T (1990) Relationship
between CA 125 and progesterone production in women with ovarian
carcinoma. Cancer 65: 2058–2063.
33. (1995) NIH consensus conference. Ovarian cancer. Screening, treatment,
and follow-up. NIH Consensus Development Panel on Ovarian Cancer.
JAMA 273: 491–497.
34. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351: 2519–2529.
35. Schilthuis MS, Aalders JG, Bouma J, Kooi H, Fleuren GJ, et al. (1987) Serum
CA 125 levels in epithelial ovarian cancer: relation with ﬁndings at second-
look operations and their role in the detection of tumour recurrence. Br J
Obstet Gynaecol 94: 202–207.
36. Weir EG, Partin AW, Epstein JI (2000) Correlation of serum prostate
speciﬁc antigen and quantitative immunohistochemistry. J Urol 163: 1739–
1742.
37. Meyer T, Rustin GJ (2000) Role of tumour markers in monitoring epithelial
ovarian cancer. Br J Cancer 82: 1535–1538.
38. Vesey SG, Goble M, Ferro MA, Stower MJ, Hammonds JC, et al. (1990)
Quantiﬁcation of prostatic cancer metastatic disease using prostate-
speciﬁc antigen. Urology 35: 483–486.
39. Klug TL, Bast RC Jr., Niloff JM, Knapp RC, Zurawski VR Jr. (1984)
Monoclonal antibody immunoradiometric assay for an antigenic determi-
nant (CA 125) associated with human epithelial ovarian carcinomas. Cancer
Res 44: 1048–1053.
40. Urban N, McIntosh MW, Andersen M, Karlan BY (2003) Ovarian cancer
screening. Hematol Oncol Clin North Am 17: 989–1005, ix.
41. McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, et al. (2004)
Combining CA 125 and SMR serum markers for diagnosis and early
detection of ovarian carcinoma. Gynecol Oncol 95: 9–15.
42. Winter ME (2004) Basic clinical pharmacokinetics. Baltimore: Lippincott
Williams & Wilkins.
43. Munoz-de-Toro M, Durando M, Beldomenico PM, Beldomenico HR, Kass L,
et al. (2006) Estrogenic microenvironment generated by organochlorine
residues in adipose mammary tissue modulates biomarker expression in
ERalpha-positive breast carcinomas. Breast Cacncer Res 8: R47.
44. Faca VM, Ventura AP, Fitzgibbon MP, Pereira-Faca SR, Pitteri SJ, et al.
(2008) Proteomic analysis of ovarian cancer cells reveals dynamic processes
of protein secretion and shedding of extra-cellular domains. PLoS ONE 3:
e2425. doi:10.1371/journal.pone.0002425
45. Haab F, Meulemans A, Boccon-Gibod L, Dauge MC, Delmas V, et al. (1995)
Clearance of serum PSA after open surgery for benign prostatic hyper-
trophy, radical cystectomy, and radical prostatectomy. Prostate 26: 334–
338.
PLoS Medicine | www.plosmedicine.org August 2008 | Volume 5 | Issue 8 | e170 1296
Mathematical Modeling of Blood Biomarker LevelsEditors’ Summary
Background. Cancers—disorganized masses of cells that can occur in
any tissue—develop when cells acquire genetic changes that allow them
to grow uncontrollably and to spread around the body (metastasize). If a
cancer (tumor) is detected when it is small, surgery can often provide a
cure. Unfortunately, many cancers (particularly those deep inside the
body) are not detected until they are large enough to cause pain or
other symptoms by pressing against surrounding tissue. By this time, it
may be impossible to remove the original tumor surgically and there
may be metastases scattered around the body. In such cases, radio-
therapy and chemotherapy can sometimes help, but the outlook for
patients whose cancers are detected late is often poor. Consequently,
researchers are trying to develop early detection tests for different types
of cancer. Many tumors release specific proteins—‘‘cancer bio-
markers’’—into the blood and the hope is that it might be possible to
find sets of blood biomarkers that detect cancers when they are still
small and thus save many lives.
Why Was This Study Done? For most biomarkers, it is not known how
the amount of protein detected in the blood relates to tumor size or how
sensitive the assays for biomarkers must be to improve patient survival.
In this study, the researchers develop a ‘‘linear one-compartment’’
mathematical model to predict how large tumors need to be before
blood biomarkers can be used to detect them and test this model using
published data on two established cancer biomarkers—CA125 and
prostate-specific antigen (PSA). CA125 is used to monitor the progress of
patients with ovarian cancer after treatment; ovarian cancer is rarely
diagnosed in its early stages and only one-fourth of women with
advanced disease survive for 5 y after diagnosis. PSA is used to screen for
prostate cancer and has increased the detection of this cancer in its early
stages when it is curable.
What Did the Researchers Do and Find? To develop a model that
relates secreted blood biomarker levels to tumor sizes, the researchers
assumed that biomarkers mix evenly throughout the patient’s blood,
that cancer cells secrete biomarkers into the fluid that surrounds them,
that 0.1%–20% of these secreted proteins enter the blood at a
continuous rate, and that biomarkers are continuously removed from
the blood. The researchers then used their model to calculate the
smallest tumor sizes that might be detectable with these biomarkers by
feeding in existing data on CA125 and on PSA, including assay detection
limits and the biomarker secretion rates of cancer cells growing in dishes.
When only tumor cells secreted the biomarker and 10% of the secreted
biomarker reach the blood, the model predicted that ovarian tumors
between 0.11 mm
3 (smaller than a grain of salt) and nearly 4,000 mm
3
(about the size of a cherry) would be detectable by measuring CA125
blood levels (the range was determined by varying the amount of
biomarker secreted by the tumor cells and the assay sensitivity); for
prostate cancer, the detectable tumor sizes ranged from similar lower
size to about 130 mm
3 (pea-sized). However, healthy cells often also
secrete small quantities of cancer biomarkers. With this condition
incorporated into the model, the estimated detectable tumor sizes (or
total tumor burden including metastases) ranged between grape-sized
and melon-sized for ovarian cancers and between pea-sized to about
grapefruit-sized for prostate cancers.
What Do These Findings Mean? The accuracy of the calculated tumor
sizes provided by the researchers’ mathematical model is limited by the
lack of data on how tumors behave in the human body and by the many
assumptions incorporated into the model. Nevertheless, the model
predicts detection limits for ovarian and prostate cancer that broadly
mirror the clinical performance of both biomarkers. Somewhat worry-
ingly, the model also indicates that a tumor may have to be very large for
blood biomarkers to reveal its presence, a result that could limit the
clinical usefulness of biomarkers, especially if they are secreted not only
by tumor cells but also by healthy cells. Given this finding, as more
information about how biomarkers behave in the human body becomes
available, this model (and more complex versions of it) should help
researchers decide which biomarkers are likely to improve early cancer
detection and patient outcomes.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050170.
  The US National Cancer Institute provides a brief description of what
cancer is and how it develops and a fact sheet on tumor markers; it
also provides information on all aspects of ovarian and prostate cancer
for patients and professionals, including information on screening and
testing (in English and Spanish)
  The UK charity Cancerbackup also provides general information about
cancer and more specific information about ovarian and prostate
cancer,includingthe useof CA125andPSA for screeningandfollow-up
  The American Society of Clinical Oncology offers a wide range of
information on various cancer types, including online published
articles on the current status of cancer diagnosis and management
from the educational book developed by the annual meeting faculty
and presenters. Registration is mandatory, but information is free
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